A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename)

Jornal de Pediatria

Volumn 89, Issue 2, 2013, Pages 171-178

  Coelho, Helena Lutéscia L ^a   Rey, Luís Carlos ^a   De Medeiros, Marina S G ^a   Barbosa, Ronaldo A ^a   Da Cruz Fonseca, Said G ^a   Da Costa, Patricia Q ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Centro Universitário Estácio do Ceará   (Brazil)

Author keywords

Child; Drugs, essential; Health public policy; Infant; Newborn; Pharmaceutical preparations

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; ANTIPROTOZOAL AGENT; ANTITRYPANOSOMAL AGENT; CAFFEINE CITRATE; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; COTRIMOXAZOLE; DIAZEPAM; DIURETIC AGENT; ESSENTIAL DRUG; IBUPROFEN; JAPANESE ENCEPHALITIS VACCINE; LORAZEPAM; MINERAL; MUSCLE RELAXANT AGENT; PENTAMIDINE; PHENOBARBITAL; PHENYTOIN; PROSTAGLANDIN E; RESPIRATORY TRACT AGENT; SALBUTAMOL SULFATE; TRIMETHOPRIM; UNINDEXED DRUG; VITAMIN;

AFRICAN TRYPANOSOMIASIS; ARTICLE; BRAZIL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG POTENCY; ESSENTIAL DRUGS LIST; HEALTH CARE; HUMAN; NEWBORN CARE; PNEUMOCYSTIS PNEUMONIA; WORLD HEALTH ORGANIZATION;

EID: 84876873378     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jped.2013.03.004     Document Type: Article

References (44)

1. World Health Organization (WHO). Medicines: essential medicines. Fact sheet no. 325. Geneve: WHO; 2010 [accessed 9 Aug 2012]. Available from: http://www.who.int/mediacentre/factsheets/fs325/en/index.html
2. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol. 2005;59: 674-6.
3. Cram A, Breitkreutz J, Desset-Brèthes S, Nunn T, Tuleu C; European Paediatric Formulation Initiative (EuPFI). Challenges of developing palatable oral paediatric formulations. Int J Pharm. 2009;365: 1-3.
4. Yewale VN, Dharmapalan D. Promoting appropriate use of drugs in children. Int J Pediatr. 2012;2012: 906570.
5. World Health Organization (WHO). WHO policy perspectives on medicines: the selection of essential medicines. Geneva: WHO; 2002 [accessed 9 Aug 2012]. Available from: http://apps.who. int/medicinedocs/pdf/s2296e/s2296e.pdf
6. European Medicines Agency. Report from the Paediatric Committee on its first anniversary. London: European Medicines Agency; 2008 [accessed 9 Aug 2012]. Available from: http://www.ema.europa.eu/pdfs/human/pdco/34788408en.pdf
7. Nunn T. The National Institute for Health Research Medicines for Children Research Network. Paediatr Drugs. 2009;11: 14-5.
8. Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008;30: 2133-45.
9. Costello I, Long PF, Wog IC, Tuleu C, Yeung V, editores. Paediatric drug handling. London: Pharmaceutical Press; 2007.
10. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Política nacional de medicamentos. Brasília: Ministério da Saúde; 2001. (Série C. Projetos, Programas e Relatórios, no. 25)
11. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais: Rename. 6th ed. Brasília: Ministério da Saúde; 2008. (Série B. Textos Básicos de Saúde)
12. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais: Rename. 7th ed. Brasília: Ministério da Saúde; 2010. (Série B. Textos Básicos de Saúde)
13. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais: Rename. 8th ed. Brasília: Ministério da Saúde; 2012. (Série B. Textos Básicos de Saúde)
14. Costa PQ, Lima JE, Coelho HL. Prescription and preparation of drugs without adequate formulation for children: a hospitalbased study. Braz J Pharm Sci. 2009;45: 57-66.
15. Costa PQ, Rey LC, Coelho HL. Lack of drug preparations for use in children in Brazil. J Pediatr (Rio J). 2009;85: 229-35.
16. Santos DB, Clavenna A, Bonati M, Coelho HL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64: 1111-8.
17. Santos DB, Cruz AA, de Magalhães Simões S, Rodrigues LC, Camargos PA, Coelho HL, et al. Pattern of asthma medication use among children from a large urban center in Brazil. Eur J Clin Pharmacol. 2012;68: 73-82.
18. Carvalho PR, Carvalho CG, Alievi PT, Martinbiancho J, Trotta EA. Identificação de medicamentos "não apropriados para crianças" em prescrições de unidade de tratamento intensivo pediátrica. J Pediatr (Rio J). 2003;79: 397-402.
19. Peterlini MA, Chaud MN, Pedreira M da L. Drug therapy orphans: the administration of intravenous drugs in hospitalized children. Rev Lat Am Enfermagem. 2003;11: 88-95.
20. Gonçalves AC, Caixeta CM, Reis AM. Analysis of the use of systemic antimicrobial drugs in children and teenagers in two teaching hospitals. Rev Ciênc Farm Básica Apl. 2009;30: 177-82.
21. World Health Organization (WHO). WHO model list of essential medicines for children - 3rd list. Geneva: WHO; 2011 [accessed 9 Aug 2012]. Available from: http://whqlibdoc.who.int/hq/2011/a95054-eng.pdf
22. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients - FDA. Final rule. Fed Regist. 1998;63: 66631-72.
23. National Institute of Child Health and Human Development. Pediatric Pharmacology Research Units Network [accessed 9 Aug 2012]. Available from: http://www.nichd.nih.gov/research/supported/ppru1.cfm
24. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-15, 111 Stat. 2296 (November 21, 1997) [accessed 9 Aug 2012]. Available from: http://www.fda.gov/Regulatory I n f o rma t i o n /L e g i s l a t i o n /F e d e r a l F o o d D r u g a n d CosmeticActFDCAct/ SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm
25. Buck ML. The FDA Modernization Act of 1997: impact on pediatric medicine. Pediatr Pharm. 2000;6.
26. Best Pharmaceuticals for Children Act, Pub. L. No. 107-9, Stat. 1789 (January 4, 2002) [accessed 9 Aug 2012]. Available from: http://www.fda.gov/ downloads/Drugs/Development ApprovalProcess/DevelopmentResources/UCM049874.pdf
27. Zajicek A. The National Institutes of Health and the Best Pharmaceuticals for Children Act. Paediatr Drugs. 2009;11: 45-7.
28. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823 (September 27, 2007) [accessed 9 Aug 2012]. Available from: http://frwebgate.access.gpo.gov/c g i - b i n /g e t d o c . c g i? d b n a m e = 1 1 0 - c o n g - p u b l i c - laws&docid=f:publ085.110
29. Pediatric Pharmacy Advocacy Group (PPAG) [accessed 9 Aug 2012]. Available from: http://www.ppag.org/en/art/348/
30. Koren G, Rieder M, MacLeod SM. The global alliance for pediatric pharmacology: the future is here and now. Paediatr Drugs. 2009;11: 4-5.
31. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union [accessed 9 Aug 2012]. Available from: http://ec.europa.eu/health/files/ eudralex/vol-1/reg-2006-1901/reg-2006-1901- en.pdf
32. European Medicines Agency. Paediatric Committee (PDCO) [accessed 9 Aug 2012]. Available from: http://www.emea. europa.eu/htms/general/contacts/PDCO/ PDCO.html
33. Duarte D, Fonseca H. Better medicines in Paediatrics. Acta Pediatr Port. 2008;39: 17-22.
34. World Health Organization (WHO). Better medicines for children: report by the Secretariat. Sixtieth World Health Assembly. Geneve: WHO; 2007 [accessed 9 Aug 2012]. Available from: http://apps.who.int/gb/ebwha/pdf-files/WHA60/A60-25- en.pdf
35. Gazarian M. Delivering better medicines to children: need for better integration between the science, the policy, and the practice. Paediatr Drugs. 2009;11: 41-4.
36. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343: 674-81.
37. Sankar MJ, Agarwal R, Deorari AK, Paul VK. Sepsis in the newborn. Indian J Pediatr. 2008;75: 261-6.
38. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164: 552-8.
39. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285: 2114-20.
40. Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012;129:e40-5.
41. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J. 2003; 22: 787-94.
42. Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;97: 24-33.
43. Schirm E, Tobi H, de Vries TW, Choonara I, De Jong-van den Berg LT. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2003;92: 1486-9.
44. Beggs SA, Cranswick NE, Reed MD. Improving drug use for children in the developing world. Arch Dis Child. 2005;90: 1091-3.